文献速递血脂与心血管预防

低剂量瑞舒伐他汀与安慰剂及膳食补充剂对血脂和炎症标志物的比较效果

Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers.
PubMed 文献 · J Am Coll Cardiol · 2022-11-06

这项单中心、前瞻性、随机、单盲临床试验纳入无ASCVD病史、LDL-C 70-189 mg/dL且10年ASCVD风险增高的成人,比较瑞舒伐他汀5 mg每日一次与安慰剂及6种常见补充剂对血脂和炎症标志物的影响。主要终点为28天后LDL-C较基线的百分比变化,结果显示瑞舒伐他汀降低LDL-C的幅度显著大于所有补充剂和安慰剂(P<0.001),而补充剂与安慰剂相比均无显著降低LDL-C。

要点

  • 瑞舒伐他汀5 mg每日一次降低LDL-C显著优于安慰剂及鱼油、肉桂、大蒜、姜黄、植物甾醇、红曲。
  • 与安慰剂相比,瑞舒伐他汀降低LDL-C的差值为-35.2%(95%CI:-41.3%至-29.1%;P<0.001)。
  • 6种膳食补充剂与安慰剂相比均未显示显著降低LDL-C,不良事件率各组相似。

核心结论

  • 在10年ASCVD风险增高的成人中,瑞舒伐他汀5 mg每日一次降低LDL-C显著优于安慰剂、鱼油、肉桂、大蒜、姜黄、植物甾醇和红曲。

研究设计与样本

  • 单中心、前瞻性、随机、单盲临床试验,纳入无ASCVD病史、LDL-C 70-189 mg/dL且10年ASCVD风险增高的成人,共190例完成研究。
  • 参与者随机接受瑞舒伐他汀5 mg每日一次、安慰剂、鱼油、肉桂、大蒜、姜黄、植物甾醇或红曲。
  • 主要终点为28天后LDL-C较基线的百分比变化,采用层次化分析协方差比较瑞舒伐他汀与安慰剂及每种补充剂。

主要发现

  • 瑞舒伐他汀降低LDL-C的百分比大于所有补充剂和安慰剂(P<0.001)。
  • 瑞舒伐他汀与安慰剂相比,LDL-C降低差值为-35.2%(95%CI:-41.3%至-29.1%;P<0.001)。
  • 与安慰剂相比,所有膳食补充剂均未显示LDL-C显著降低。
  • 不良事件率在各研究组间相似。

关键数值与推荐

  • 瑞舒伐他汀5 mg每日一次与安慰剂相比,LDL-C降低差值为-35.2%(95%CI:-41.3%至-29.1%;P<0.001)。
  • 所有膳食补充剂与安慰剂相比,LDL-C降低均无统计学显著性。

临床怎么用

  • 对于有降脂指征且10年ASCVD风险增高的成人,低剂量瑞舒伐他汀5 mg每日一次可显著降低LDL-C。
  • 常见膳食补充剂(鱼油、肉桂、大蒜、姜黄、植物甾醇、红曲)不宜替代他汀用于降低LDL-C。

局限性

  • 研究为单中心、单盲设计,样本量190例,随访28天,仅评估短期效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Supplements are commonly used by individuals with indications for lipid-lowering therapy, but evidence of their effectiveness to lower low-density lipoprotein cholesterol (LDL-C) is lacking, particularly when compared with statins. OBJECTIVES: The trial objective was to compare the efficacy of a low-dose statin with placebo and 6 common supplements in impacting lipid and inflammatory biomarkers. METHODS: This was a single-center, prospective, randomized, single-blind clinical trial among adults with no history of atherosclerotic cardiovascular disease (ASCVD), an LDL-C of 70 to 189 mg/dL, and an increased 10-year risk of ASCVD. Participants were randomized to rosuvastatin 5 mg daily, placebo, fish oil, cinnamon, garlic, turmeric, plant sterols, or red yeast rice. The primary endpoint was the percent change in LDL-C from baseline for rosuvastatin 5 mg daily compared with placebo and each supplement after 28 days. The primary endpoint was evaluated in a hierarchical fashion with rosuvastatin first compared with placebo, then each supplement in a prespecified order using analysis of covariance. RESULTS: A total of 190 participants completed the study. The percent LDL-C reduction with rosuvastatin was greater than all supplements and placebo (P < 0.001). The difference in LDL-C reduction with rosuvastatin compared with placebo was -35.2% (95% CI: -41.3% to -29.1%; P < 0.001). None of the dietary supplements demonstrated a significant decrease in LDL-C compared with placebo. Adverse event rates were similar across study groups. CONCLUSIONS: Among individuals with increased 10-year risk for ASCVD, rosuvastatin 5 mg daily lowered LDL-C significantly more than placebo, fish oil, cinnamon, garlic, turmeric, plant sterols, and red yeast rice. (Supplements, Placebo, or Rosuvastatin Study [SPORT]; NCT04846231).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Laffin LJ, Bruemmer D, Garcia M, et al. Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers. J Am Coll Cardiol. 2022. PMID: 36351465. doi:10.1016/j.jacc.2022.10.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。